Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
M&A / Property

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

By The Northwire Desk — AI Analysis Oct 22, 2025 · 15:30 NTLX · None None
NTLX · Price

Executive Summary

  • SciSparc Ltd. acquired a controlling interest (~75% non‑diluted, ~84.5% partially diluted) in NeuroThera Labs Inc. through a reverse takeover, receiving 63.3 M common shares, 4 M payment warrants and 48 M contingent rights.
  • The transaction triggered an early‑warning filing under NI 62‑103; the deemed value of the acquired shares is $0.25 per share.
  • SciSparc states the holdings are for investment purposes with no immediate plans to buy or sell additional securities, though future actions may depend on market conditions.

Key Details

  • Acquired Securities: 63,300,000 common shares of NeuroThera Labs Inc.; 4,000,000 common share purchase warrants (price $0.25 per share, exercisable until 22 Oct 2030); 48,000,000 contingent rights exercisable into up to an equal number of shares upon meeting predetermined milestones.
  • Ownership Percentage Post‑Transaction: ~75% on a non‑diluted basis; 84.53% on a partially diluted basis.
  • Consideration / Valuation: Deemed value of the common shares is $0.25 per share; no cash consideration disclosed.
  • Qualifying Transaction: Transfer of all SciSparc Nutraceuticals Inc. (“SNI”) shares held by SciSparc (representing 50.86% of SNI) and certain SciSparc assets to NeuroThera Labs Inc., completing the reverse takeover.
  • Regulatory Filing: Early warning report filed pursuant to NI 62‑103; available on SEDAR+ or from SciSparc contact information provided.
  • Future Intentions: Holdings are for investment purposes; no current plan to acquire additional securities or dispose of existing holdings, but may act based on market conditions or strategic considerations.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from None

Jun 30, 2026 · 18:00

Pre-revenue neurology and cannabis-tech company raises capital at a discount to fund operations and settle parent company debt.

Financings Jun 03, 2026 · 17:15

Neurothera Closes Cashless Quantum-Tech Acquisition, But Dilution and Clinical Stage Risks Keep Upside Capped

M&A / Property May 27, 2026 · 08:00

Neurothera Labs Confirms Acquisition Closing Amidst Significant Equity Dilution and Regulatory Scrutiny

M&A / Property Mar 16, 2026 · 07:31

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

M&A / Property Mar 11, 2026 · 07:30

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Other Mar 10, 2026 · 07:30

Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.

M&A / Property